Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$1.99 USD
-0.01 (-0.50%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.98 -0.01 (-0.50%) 6:04 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.99 USD
-0.01 (-0.50%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.98 -0.01 (-0.50%) 6:04 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 217.6% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Tenaya Therapeutics, Inc. (TNYA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 367.7% upside potential for Tenaya Therapeutics, Inc. (TNYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA)
by Zacks Equity Research
Tenaya Therapeutics (TNYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.